Navigation Links
BioMS Medical Announces 2008 Year End Results
Date:3/17/2009

its primary endpoint at the end of the trial. Based on the DSMB decision, Eli Lilly and Company (Lilly) provided a US $10 million milestone payment to BioMS as part of the terms of the licensing and collaboration agreement. BioMS anticipates MAESTRO-01 will be completed in 2009 with results from the trial expected in the second half of this year. - MAESTRO-02: Eligible patients who have successfully completed MAESTRO-01 may choose to receive dirucotide on an un-blinded basis in this open-label follow-on study. To date, approximately 95% of the eligible patients who have successfully completed the MAESTRO-01 trial have enrolled in this follow-on study. - MAESTRO-03: Enrollment was initiated in June, 2007 and completed on August 1, 2008 for this pivotal U.S. phase III trial of approximately 510 SPMS patients at 67 sites across the U.S. To date, the DSMB has conducted three reviews of the data from this trial and recommended it continue. The next DSMB review is expected to take place in the second quarter of fiscal 2009. - MINDSET-01: MINDSET-01 was a randomized, double-blind study that recruited 218 relapsing-remitting MS patients at 24 trial sites in six countries across Europe. BioMS recently announced that the top line results of this exploratory study did not meet its primary endpoint of effecting annualized relapse rate or associated secondary magnetic resonance imaging (MRI) endpoints. Dirucotide did meet certain secondary endpoints related to the progression of the disease, including mean change from baseline in the EDSS and the MS Functional Composite (MSFC) score. Changes in EDSS and MSFC are primary and secondary outcomes in the ongoing phase III SP
'/>"/>
SOURCE BioMS Medical Corp.
Copyright©2009 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7 8 9 10 11

Related biology technology :

1. BioMS Medical warrant extension
2. BioMS Medical to present at BIO CEO and Investor Conference
3. BioMS Medical reports results of exploratory phase II trial of dirucotide in relapsing remitting multiple sclerosis
4. BioMS Medical recognized at Scrip Awards 2008
5. BioMS Medical Announces Third Quarter 2008 Results
6. BioMS Medical to present at Rodman and Renshaw Annual Healthcare Conference
7. BioMS Medicals relapsing-remitting multiple sclerosis trial receives positive review from Data Safety Monitoring Board
8. BioMS Medicals phase III U.S. multiple sclerosis trial receives positive safety review from Data Safety Monitoring Board
9. BioMS Medical announces receipt of milestone payment from Eli Lilly and Company
10. BioMS Medical to present at Sachs Associates Biotech in Europe Forum
11. BioMS Medical to present at UBS Global Life Sciences Conference
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:1/22/2015)... 22, 2015  Transwestern | RBJ today announces the firm brokered ... for Shire a leading biopharmaceutical company, at Two Ledgemont Center ... Robert Richards , president, and Brian Cohen , ... entire five-floor building at 95 Hayden Ave. Photo ...
(Date:1/22/2015)... Cambridge Semantics, the leading provider of smart data solutions driven ... record-breaking year across the board for the company. , ... and our Smart Data solutions, our customers were able to ... to record growth for the company in 2014,” said Alok ...
(Date:1/22/2015)... / Rootstown, OH (PRWEB) January 22, 2015 ... platform, announced today that it has received AOAC-PTM Certifications for ... O1O3, O111, O121, and O145; collectively referred to as STEC ... O157, at 1 colony forming unit (cfu) per 325 g ...
(Date:1/22/2015)... Dr. Greg Leyer of UAS Labs recently was invited ... seminar on probiotics in San Diego, CA. , The ... for health care professionals. This year’s pre-conference seminar was held ... health. Dr. Leyer spoke about the emerging topics and science ...
Breaking Biology Technology:Transwestern | RBJ Advises Shire in 202,000 SF Lease, Creating Boston's Largest Suburban Biotech Campus 2Cambridge Semantics Announces Record Results for 2014 2Crystal Diagnostics Awarded AOAC-PTM Accreditation for the Rapid Detection of “Big 6” E.coli Food Pathogens 2
... HILL, N.C., May 30 Given the increasing,challenges ... continue to seek external opportunities to grow their ... experts have,found the importance of proper integration of ... in the newly published study, "M&A Integration,Excellence: What ...
... N.J., May 30 Pharmacopeia (Nasdaq:,PCOP), an innovator ... therapeutics, announced today that it is implementing the ... resources on the company,s clinical,and later-stage discovery programs. ... 15 percent through attrition and,termination of positions as ...
... PCYC ) today announced that it has received ... regained compliance with Marketplace Rule,4450(a)(5) (the "Rule") relating to ... Company,s common stock. Nasdaq had previously notified the,company on ... to maintain a,minimum bid price of at least $1.00 ...
Cached Biology Technology:Bio-Pharma Industry Experts Deliver M&A Value Through Integration Excellence 2Pharmacopeia Advances Strategic Plan to Focus Resources on Development and Later-Stage Discovery Programs 2Pharmacopeia Advances Strategic Plan to Focus Resources on Development and Later-Stage Discovery Programs 3Pharmacopeia Advances Strategic Plan to Focus Resources on Development and Later-Stage Discovery Programs 4
(Date:12/17/2014)... 2014  HITLAB SM announced today its completion of ... adherence to current U.S. Food and Drug Administration (FDA) ... device and smart phone application trials utilizing the highest ... "HITLAB is determined to improve global healthcare access, quality, ...
(Date:12/17/2014)... DENVER , Dec. 16, 2014  Automation is fundamentally ... evident than at international borders. Over the past decade, ... veteran travelers to self process through border control via ... increasing number of airports, seaports, and land borders across ...
(Date:12/11/2014)... 09, 2014 Research and Markets , ... ) has announced the addition of the "Biometrics ... One major trend emerging in this ... biometric systems utilize more than one characteristic of an ...
Breaking Biology News(10 mins):HITLAB Completes GCP Audit for FDA Smart Device & App Compliance 2Automated Border Control (ABC) Transforms the Global Travel Experience With More Than 2500 ABC eGates and APC Kiosks Deployed In Airports, Seaports, and Land Borders Worldwide 2Biometrics Market in India 2015-2019: Key Vendors are 3M Cogent, NEC, Safran and Suprema 2
... New Rochelle, NY, May 18, 2011Many gene therapy strategies designed ... carrying a disease-causing genetic mutation rely on a modified virus ... platform that is well suited for in vivo delivery of ... novel therapies move closer to commercialization, so do the methods ...
... genetic ,wiring, that helps a seed to decide on the ... the first time. Plant biologists at The University of ... germination is responsible for another important decision in the life ... discovery throws light on the genetic mechanisms that plants use ...
... University of Sheffield have developed pigment-free, intensely coloured polymer ... or banknotes due to their difficulty to copy. ... exhibit intense colour due to their structure, similar to ... butterfly wings. These colours were created by highly ...
Cached Biology News:Gene therapy success depends on ability to advance viral delivery vectors to commercialization 2Nottingham scientists reveal genetic 'wiring' of seeds 2Rainbows without pigments offer new defense against fraud 2
... The product contains 5 ml Dynabeads ... with p-toluenesulphonyl (tosyl) reactive groups. For coupling ... absorbed hydrophobically on initial coupling with covalent ... and sulphydryll groups (SH)) occurringovernight. Coupling ...
cysteine and glycine-rich protein 2,...
... pan B (B220), 4.5 m, coated ... efficient positive isolation or depletion of ... or lymph node cell suspensions. B220 ... cells and lytically active subsets of ...
Gap junction protein, beta 2, 26kDa (connexin 26) Antigen: Peptide...
Biology Products: